WTF with ALA: What are iNKT cell therapies?

What are iNKT cell therapies, how do they work, and why are they promising for cancer treatment?

Arovella Therapeutics (ASX:ALA) managing director and CEO Dr Michael Baker joins host Tylah Tully to to explore these questions and more.

The company’s focused on developing its innovative invariant natural killer T (iNKT) cell therapy platform, with its lead program, ALA-101, targeting blood cancers.

While Arovella didn’t invent iNKT cells – they occur naturally in the human body – the company is harnessing their unique properties to fight cancer.

Baker explains how iNKT cells could transform the patient experience over the next five to ten years and potentially treat both deadly blood cancers and solid tumours.

While Arovella Therapeutics is a Stockhead advertiser, it did not sponsor this content.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.